Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

Annals of the American Thoracic Society

Volumn 11, Issue 4, 2014, Pages 531-536

  Katz, Lynn E ^a   Gleich, Gerald J ^b   Hartley, Benjamin F ^c   Yancey, Steven W ^a   Ortega, Hector G ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anti IL 5; Eosinophils; Phenotype; Severe asthma

Indexed keywords

CORTICOSTEROID; MEPOLIZUMAB; PLACEBO; ANTIASTHMATIC AGENT; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASTHMA; BLOOD SAMPLING; DISEASE EXACERBATION; EOSINOPHIL COUNT; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERE EOSINOPHILIC ASTHMA; SMOKING; SPUTUM ANALYSIS; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; CYTOLOGY; DISEASE COURSE; EOSINOPHIL; EOSINOPHILIA; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SPUTUM; TREATMENT OUTCOME;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; DISEASE PROGRESSION; EOSINOPHILIA; EOSINOPHILS; FEMALE; HUMANS; INTERLEUKIN-5; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SPUTUM; TREATMENT OUTCOME;

EID: 84903608027     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201310-354OC     Document Type: Article

References (22)

1. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-2466.
2. Nakamura Y. Developmental current and future therapy for severe asthma. Inflamm Allergy Drug Targets 2013;12:54-60.
3. Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med 2012;13:305-312.
4. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-1132.
5. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-659.
6. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-1098.
7. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013;12:117-129.
8. Hansbro PM, Scott GV, Essilfie AT, Kim RY, Starkey MR, Nguyen DH, Allen PD, Kaiko GE, Yang M, Horvat JC, et al. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Investig Drugs 2013;22:49-69.
9. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
10. Wadsworth S, Sin D, Dorscheid D. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. J Asthma Allergy 2011;4:77-86.
11. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360: 1715-1721. (Pubitemid 35447900)
12. Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med 2013;7:33-42.
13. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention [Internet]. [accessed 2013 Dec 15]. Available from: http://www.ginasthma.org/local/uploads/files/GINA-Report-March13.pdf
14. Spector SL, Tan RA. Is a single blood eosinophil count a reliable marker for "eosinophilic asthma?". J Asthma 2012;49:807-810.
15. Sorice F, De Simone C. Human eosinophil heterogeneity. Ric Clin Lab 1986;16:429-434.
16. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012;129(3 Suppl):S9-S23.
17. Farahi N, Singh NR, Heard S, Loutsios C, Summers C, Solanki CK, Solanki K, Balan KK, Ruparelia P, Peters AM, et al. Use of 111-indium-labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects. Blood 2012;120: 4068-4071.
18. Acland JD, Gould AH. Normal variation in the count of circulating eosinophils in man. J Physiol 1956;133:456-466.
19. Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM, Peters SP, Meyers DA, Bleecker ER; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013;132:72-80.
20. Ullmann N, Bossley CJ, Fleming L, Silvestri M, Bush A, Saglani S. Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma. Allergy 2013;68:402-406.
21. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, et al.; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-654, e10.
22. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013; 132:821-827, e1-e5.